Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Current Deferred Revenue: 2010-2025

Historic Current Deferred Revenue for OptimizeRx (OPRX) over the last 16 years, with Q3 2025 value amounting to $25.1 million.

  • OptimizeRx's Current Deferred Revenue rose 822.3% to $25.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $25.1 million, marking a year-over-year increase of 822.3%. This contributed to the annual value of $4.3 million for FY2024, which is 239302.33% up from last year.
  • OptimizeRx's Current Deferred Revenue amounted to $25.1 million in Q3 2025, which was up 822.3% from $41.0 million recorded in Q2 2025.
  • In the past 5 years, OptimizeRx's Current Deferred Revenue registered a high of $41.0 million during Q2 2025, and its lowest value of $164000.0 during Q4 2022.
  • For the 5-year period, OptimizeRx's Current Deferred Revenue averaged around $7.3 million, with its median value being $904000.0 (2024).
  • As far as peak fluctuations go, OptimizeRx's Current Deferred Revenue tumbled by 8820.06% in 2022, and later surged by 1220984.0% in 2024.
  • Over the past 5 years, OptimizeRx's Current Deferred Revenue (Quarter) stood at $1.4 million in 2021, then crashed by 88.2% to $164000.0 in 2022, then rose by 4.88% to $172000.0 in 2023, then soared by 2393.02% to $4.3 million in 2024, then skyrocketed by 485.31% to $25.1 million in 2025.
  • Its Current Deferred Revenue was $25.1 million in Q3 2025, compared to $41.0 million in Q2 2025 and $35.3 million in Q1 2025.